Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18660667 | DNA POLYMERASE MUTANT SUITED TO NUCLEIC ACID AMPLIFICATION FROM RNA | May 2024 | April 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18628140 | ENGINEERED GLUCOSYLTRANSFERASES | April 2024 | April 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18393303 | CASZ COMPOSITIONS AND METHODS OF USE | December 2023 | December 2024 | Abandon | 12 | 1 | 1 | No | No |
| 18569989 | ENZYMATIC METHOD FOR THE PRODUCTION OF L-GLUFOSINATE P-ALKYL ESTERS | December 2023 | June 2025 | Allow | 18 | 3 | 1 | Yes | No |
| 18521466 | POLYMERASE COMPOSITIONS AND KITS, AND METHODS OF USING AND MAKING THE SAME | November 2023 | April 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18478512 | TELA VARIANTS, COMPOSITIONS, AND METHODS | September 2023 | April 2024 | Allow | 6 | 2 | 1 | Yes | No |
| 18476104 | MUTANT POLYMERASES AND USES THEREOF | September 2023 | January 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18472046 | Compositions and Methods Related to Nucleic Acid Synthesis | September 2023 | April 2025 | Abandon | 19 | 2 | 0 | No | No |
| 18464955 | POLYMERASE MUTANTS AND USE WITH 3'-OH UNBLOCKED REVERSIBLE TERMINATORS | September 2023 | February 2024 | Allow | 5 | 1 | 0 | No | No |
| 18462868 | Vaccinia Capping Enzyme Compositions and Methods | September 2023 | January 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18365105 | EVOLUTION OF PROTEASES | August 2023 | May 2025 | Abandon | 21 | 2 | 1 | No | No |
| 18219045 | MUTANT DNA POLYMERASE(S) WITH IMPROVED STRAND DISPLACEMENT ABILITY | July 2023 | December 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 18343131 | DNase Variants | June 2023 | May 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18343727 | PROCESSES FOR PRODUCING REDUCED COENZYME Q10 | June 2023 | November 2024 | Allow | 17 | 3 | 1 | Yes | No |
| 18195702 | T4 DNA Ligase Variants with Increased Resistance to Salt | May 2023 | May 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18298291 | Compositions and Analysis of Dephosphorylated Oligoribonucleotides | April 2023 | October 2024 | Allow | 19 | 4 | 1 | Yes | No |
| 18130012 | Process of Probe qPCR Using Taq DNA Polymerase Mutants | April 2023 | June 2024 | Allow | 14 | 4 | 0 | Yes | No |
| 18129292 | Protein Enriched Microvesicles and Methods of Making and Using the Same | March 2023 | February 2025 | Allow | 23 | 1 | 1 | Yes | No |
| 18191774 | ALDEHYDE DEHYDROGENASE VARIANTS AND METHODS OF USING SAME | March 2023 | March 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18125661 | NOVEL REVERSE TRANSCRIPTASES AND USES THEREOF | March 2023 | April 2024 | Allow | 13 | 0 | 1 | Yes | No |
| 18176502 | COMPOSITIONS AND METHODS FOR ENHANCING REVERSE TRANSCRIPTASE ACTIVITY AND/OR REDUCING THE INHIBITION OF REVERSE TRANSCRIPTASE | March 2023 | February 2025 | Allow | 23 | 1 | 1 | No | No |
| 18160952 | ENGINEERED POLYMERASES WITH REDUCED SEQUENCE-SPECIFIC ERRORS | January 2023 | August 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 18160951 | ENGINEERED POLYMERASES WITH REDUCED SEQUENCE-SPECIFIC ERRORS | January 2023 | January 2024 | Allow | 12 | 1 | 1 | Yes | No |
| 18154437 | METHOD FOR ADDING CAP STRUCTURES TO RNA USING IMMOBILIZED ENZYMES | January 2023 | March 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18069898 | CAS9 PROTEINS INCLUDING LIGAND-DEPENDENT INTEINS | December 2022 | April 2025 | Allow | 28 | 2 | 1 | Yes | No |
| 18080926 | MODIFIED �-GALACTOSIDASE | December 2022 | October 2024 | Abandon | 22 | 1 | 1 | No | No |
| 18055966 | DP04 POLYMERASE VARIANTS WITH IMPROVED ACCURACY | November 2022 | April 2025 | Abandon | 29 | 2 | 1 | No | No |
| 18048388 | MODIFIED THERMOCOCCUS POLYMERASES | October 2022 | July 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 17936144 | High Throughput Reaction Assembly | September 2022 | May 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 17935406 | POLYMERASE COMPOSITIONS & METHODS | September 2022 | July 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 17935521 | CASZ COMPOSITIONS AND METHODS OF USE | September 2022 | October 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17910349 | ENZYMES WITH IMPROVED THERMOSTABILITY FOR THE DEGRADATION OF PLASTIC PRODUCTS | September 2022 | June 2025 | Abandon | 33 | 1 | 1 | No | No |
| 17896147 | ALPHA-AMYLASE VARIANTS | August 2022 | May 2024 | Allow | 20 | 1 | 1 | No | No |
| 17894854 | POLYMERASE MUTANTS AND USE WITH 3'-OH UNBLOCKED REVERSIBLE TERMINATORS | August 2022 | July 2023 | Allow | 11 | 1 | 1 | Yes | No |
| 17808128 | ENGINEERED DEAMINASES | June 2022 | July 2024 | Allow | 25 | 1 | 1 | No | No |
| 17841429 | METHODS FOR GENOMIC INTEGRATION IN PICHIA AND OTHER HOST CELLS | June 2022 | August 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17838852 | IMMOBILIZED POLY(N)POLYMERASE | June 2022 | April 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17743859 | COMPOSITIONS AND METHODS FOR IDENTIFYING RNA BINDING POLYPEPTIDE TARGETS | May 2022 | November 2023 | Allow | 18 | 1 | 1 | Yes | No |
| 17742033 | Thermostable Variants of T7 RNA Polymerase | May 2022 | May 2024 | Allow | 24 | 2 | 1 | Yes | No |
| 17735129 | ASPERGILLUS ORYZAE AND ITS APPLICATION | May 2022 | June 2024 | Allow | 25 | 1 | 0 | Yes | No |
| 17728573 | GLYCOSYLATED LYSOSOMAL PROTEINS, METHOD OF PRODUCTION AND USES | April 2022 | November 2024 | Allow | 31 | 2 | 1 | Yes | Yes |
| 17725369 | POLYMERASE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | April 2022 | September 2024 | Allow | 29 | 3 | 1 | Yes | No |
| 17724342 | GRIFFITHSIN MUTANTS | April 2022 | April 2025 | Allow | 36 | 3 | 0 | Yes | No |
| 17705020 | ENGINEERED POLYMERASES | March 2022 | November 2024 | Allow | 32 | 4 | 1 | Yes | No |
| 17705043 | ENGINEERED POLYMERASES | March 2022 | July 2024 | Allow | 27 | 4 | 0 | Yes | No |
| 17678369 | NOVEL CRISPR-ASSOCIATED (CAS) PROTEIN | February 2022 | November 2023 | Allow | 21 | 0 | 1 | Yes | No |
| 17677655 | T4 DNA Ligase Variants with Increased Thermostability | February 2022 | August 2023 | Allow | 18 | 2 | 0 | Yes | No |
| 17676546 | TYPE II CRISPR/CAS9 GENOME EDITING SYSTEM AND THE APPLICATION THEREOF | February 2022 | September 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17675278 | T4 DNA Ligase Variants with Increased Resistance to Salt | February 2022 | May 2023 | Allow | 15 | 1 | 1 | Yes | No |
| 17673279 | PROGRAMMABLE DNA-GUIDED ARTIFICIAL RESTRICTION ENZYMES | February 2022 | April 2024 | Abandon | 26 | 1 | 1 | Yes | No |
| 17586234 | METHOD FOR ENHANCING PRODUCTION OF HOMEOPROTEIN USING INHIBITOR OF LYSOSOMAL FUNCTION | January 2022 | July 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17625395 | BIOTECHNOLOGICAL PRODUCTION OF DIOLS | January 2022 | February 2025 | Allow | 37 | 2 | 0 | Yes | No |
| 17564500 | ENGINEERED POLYMERASES FOR IMPROVED SEQUENCING | December 2021 | October 2023 | Allow | 22 | 1 | 0 | No | No |
| 17623542 | GENETICALLY MODIFIED MICROORGANISM AND METHOD FOR PRODUCING DIAMINE COMPOUND | December 2021 | May 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17563794 | PREPARATION METHOD OF HIGH-STABILITY SUPEROXIDE DISMUTASE WITH TRANSMEMBRANE CAPABILITY | December 2021 | December 2023 | Allow | 23 | 1 | 1 | Yes | No |
| 17645146 | POLYMERASE COMPOSITIONS, METHODS OF MAKING AND USING SAME | December 2021 | February 2025 | Allow | 38 | 5 | 1 | Yes | No |
| 17554012 | Compositions and Methods Related to Nucleic Acid Synthesis | December 2021 | June 2023 | Allow | 18 | 0 | 1 | Yes | No |
| 17553455 | KETOREDUCTASE POLYPEPTIDES FOR THE SYNTHESIS OF CHIRAL COMPOUNDS | December 2021 | May 2025 | Allow | 41 | 4 | 1 | Yes | No |
| 17544668 | GLUCOAMYLASES AND METHODS OF USE, THEREOF | December 2021 | January 2024 | Abandon | 26 | 2 | 0 | No | No |
| 17595643 | LINALOOL SYNTHASES | November 2021 | February 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17531220 | DNase Variants | November 2021 | April 2023 | Allow | 17 | 1 | 1 | Yes | No |
| 17523670 | RECOMBINANT POLYMERASES FOR INCORPORATION OF PROTEIN SHIELD NUCLEOTIDE ANALOGS | November 2021 | September 2023 | Allow | 22 | 1 | 1 | Yes | No |
| 17514043 | BIOSYNTHESIS OF VANILLIN FROM ISOEUGENOL | October 2021 | January 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17500831 | MODIFIED ENZYMES | October 2021 | December 2023 | Allow | 26 | 1 | 1 | Yes | No |
| 17485606 | METHOD OF SCREENING INHIBITOR OF CASPASE ACTIVITY BY LIPOPOLYSACCHARIDE | September 2021 | January 2024 | Allow | 27 | 3 | 0 | Yes | No |
| 17485004 | MODIFIED POLYMERASES FOR IMPROVED INCORPORATION OF NUCLEOTIDE ANALOGUES | September 2021 | August 2024 | Allow | 35 | 3 | 1 | Yes | Yes |
| 17437566 | PROCESS FOR PRODUCING A FERMENTATION BROTH | September 2021 | July 2024 | Allow | 35 | 2 | 1 | Yes | No |
| 17470557 | Taq DNA Polymerase Mutants for Probe qPCR | September 2021 | March 2023 | Allow | 18 | 2 | 1 | Yes | No |
| 17410647 | MODIFIED POLYMERASES FOR IMPROVED INCORPORATION OF NUCLEOTIDE ANALOGUES | August 2021 | June 2022 | Allow | 10 | 2 | 1 | Yes | No |
| 17373314 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | July 2021 | December 2024 | Abandon | 41 | 3 | 2 | No | No |
| 17421967 | RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF L-DOPA, DOPAMINE, S-NOROCLAURINE OR DERIVATIVES THEREOF | July 2021 | March 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17419091 | Phospholipase C Mutant With High Enzyme Activity | June 2021 | September 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17357442 | Methods and Compositions for Increased Capping Efficiency of Transcribed RNA | June 2021 | December 2023 | Abandon | 30 | 1 | 1 | No | No |
| 17355668 | ENZYME-PORE CONSTRUCTS | June 2021 | August 2023 | Allow | 26 | 1 | 1 | Yes | No |
| 17348127 | Vaccinia Capping Enzyme Compositions and Methods | June 2021 | June 2023 | Allow | 24 | 1 | 1 | Yes | No |
| 17338842 | ENGINEERED GLUCOSYLTRANSFERASES | June 2021 | December 2023 | Allow | 30 | 1 | 1 | No | No |
| 17303445 | MUTANT POLYMERASES AND USES THEREOF | May 2021 | August 2023 | Allow | 26 | 1 | 1 | Yes | No |
| 17327750 | Reactive persulfides mediate sulfur respiration in mitochondria via sulfide:quinone oxidoreductase | May 2021 | July 2024 | Abandon | 38 | 2 | 0 | Yes | No |
| 17319849 | NOVEL CRISPR-ASSOCIATED (CAS) PROTEIN | May 2021 | November 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 17317721 | THERMOSTABLE TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE | May 2021 | June 2024 | Allow | 37 | 4 | 1 | Yes | No |
| 17302621 | POLYMERASE COMPOSITIONS AND KITS, AND METHODS OF USING AND MAKING THE SAME | May 2021 | August 2023 | Allow | 28 | 2 | 1 | Yes | No |
| 17291272 | A NOVEL CLASS OF PIGMENTS IN ASPERGILLUS | May 2021 | September 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17244089 | Efficient Production of Steviol Glycosides in Recombinant Hosts | April 2021 | June 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17227771 | Use of Polypeptide | April 2021 | January 2024 | Abandon | 33 | 2 | 0 | No | No |
| 17225189 | DIMERIC REVERSE TRANSCRIPTASE | April 2021 | July 2023 | Allow | 28 | 1 | 1 | Yes | No |
| 17222368 | Use of Polypeptide | April 2021 | October 2023 | Abandon | 30 | 2 | 0 | No | No |
| 17221053 | POLYMERASES | April 2021 | April 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17217752 | MODIFICATION OF RNA-RELATED ENZYMES FOR ENHANCED PRODUCTION | March 2021 | February 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17280792 | FRUCTOSE-C4-EPIMERASE AND METHOD OF PRODUCING TAGATOSE USING THE SAME | March 2021 | February 2023 | Allow | 23 | 2 | 0 | Yes | No |
| 17280181 | ALDEHYDE DEHYDROGENASE VARIANTS AND METHODS OF USING SAME | March 2021 | January 2023 | Allow | 22 | 1 | 1 | Yes | No |
| 17211595 | NOVEL REVERSE TRANSCRIPTASES AND USES THEREOF | March 2021 | December 2022 | Allow | 21 | 0 | 1 | Yes | No |
| 17208286 | DNA POLYMERASE MUTANTS HAVING ENHANCED TEMPLATE DISCRIMINATION ACTIVITY | March 2021 | May 2023 | Abandon | 26 | 4 | 1 | Yes | No |
| 17199343 | MODIFIED DNA POLYMERASES FOR IMPROVED AMPLIFICATION | March 2021 | April 2023 | Allow | 25 | 1 | 1 | Yes | No |
| 17274667 | MUTANT DNA POLYMERASE(S) WITH IMPROVED STRAND DISPLACEMENT ABILITY | March 2021 | April 2023 | Allow | 25 | 2 | 1 | Yes | No |
| 17191141 | RECOMBINANT POLYMERASES FOR IMPROVED SINGLE MOLECULE SEQUENCING | March 2021 | April 2023 | Allow | 25 | 1 | 1 | Yes | No |
| 17188764 | METHODS AND COMPOSITIONS FOR GENOME ENGINEERING | March 2021 | August 2023 | Abandon | 30 | 1 | 1 | No | No |
| 17271439 | Production Of Non-Native Monounsaturated Fatty Acids In Bacteria | February 2021 | October 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 17270691 | MODULATORS OF CAS9 POLYPEPTIDES AND METHODS OF USE THEREOF | February 2021 | October 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17181230 | MODIFIED TYPE A DNA POLYMERASES | February 2021 | November 2022 | Allow | 20 | 1 | 1 | Yes | No |
| 17181787 | POLYMERASE ENZYME | February 2021 | January 2025 | Abandon | 47 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HUTSON, RICHARD G.
With a 46.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HUTSON, RICHARD G works in Art Unit 1652 and has examined 1,131 patent applications in our dataset. With an allowance rate of 57.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner HUTSON, RICHARD G's allowance rate of 57.9% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HUTSON, RICHARD G receive 2.44 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by HUTSON, RICHARD G is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +51.7% benefit to allowance rate for applications examined by HUTSON, RICHARD G. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 15.4% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 33.4% of cases where such amendments are filed. This entry rate is in the 42% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 92.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 66% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 78.0% of appeals filed. This is in the 66% percentile among all examiners. Of these withdrawals, 63.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 68.7% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 4.9% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.8% of allowed cases (in the 87% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.